|Report ID : RC-1617||Category : Healthcare||Published Date : Oct-18|
|Publisher : 9Dimen||Pages : 100||Format : PDF|
This report provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Retinoblastoma Report is to understand the market and pipeline status of the drugs around the Retinoblastoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Researcher Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Retinoblastoma. While the leading brands, companies and chemicals are considered thoroughly, Researcher report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
1. Indication Overview 2. Market Drugs Landscape 2.1 Marketed Drugs 2.2 Marketed Details of Drugs by Application Type 2.3 Marketed Details of Drugs (NDA) by Marketing Status 2.4 Marketed Details of Drugs by Patent Expiration Timeline 3. Global API Manufacturers Assessment 3.1 API Manufacturers by United States Drug Master File (US DMF) Status 3.2 API Manufacturers by US DMF Status (Drug Specific) 3.3 API Manufacturers in Europe by Country 3.4 API Manufacturers in India by State 3.5 API Manufacturers in China by Province 3.6 Marketed Details of Approved Drugs by Geography 4. Phase III Drugs Landscape 4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs 4.2 API Manufacturers by US DMF Status (Drug Specific) 5. Drugs Market Data and Forecasted Sales Figure-2018 6. Marketed Drugs for Retinoblastoma 6.1 Drug Name 6.1.1 Drug Description 6.1.2 Global Active Pharmaceutical Manufacturers for Drug 6.1.3 Approval Status of Drug 6.1.4 Patent and Exclusivity Details for Drug 6.1.5 Company Profile and Financials 7. Phase III Drugs for Retinoblastoma 7.1 Drug Name 7.1.1 Drug Description 7.1.2 United States Drug Master File (DMF) 8. Discontinued Drugs for Retinoblastoma 9. Appendix 10. Methodology 11. Consulting Services
Akasaka biz tower,
5-3-1 akasaka minato-ku,
13284 bluejacket street overland park,
KS 66213 United States